CAR-T contender Juno Therapeutics is settling in for the long haul in a race to commercialize new immunotherapies for cancer, buying up a European biotech to firm up its process on the way to late-stage development.

…read more

Source: Juno beefs up its CAR-T arsenal with an $80M biotech buyout


0 No comments